安慰剂-话题@MedSci

#安慰剂#

133篇内容 | 5035人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1304423, encodeId=5fd01304423b3, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Cancer Med：国内多中心随机双盲II期研究表明安罗替尼（Anlotinib）后线治疗较安慰剂改善晚期或转移性食管鳞癌患者的预后, objectType=article, longId=293004, objectId=d88b293004b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d88b293004b9, replyNumber=0, likeNumber=111, createdTime=2021-12-30, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d88b293004b9, moduleTitle=Cancer Med：国内多中心随机双盲II期研究表明安罗替尼（Anlotinib）后线治疗较安慰剂改善晚期或转移性食管鳞癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d88b293004b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304422, encodeId=dcc613044226b, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, objectType=article, longId=292261, objectId=67d0292261ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d0292261ff, replyNumber=0, likeNumber=103, createdTime=2021-12-21, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d0292261ff, moduleTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d0292261ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304421, encodeId=305a130442156, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=A &R: 阿托伐他汀对有症状膝骨关节炎患者膝关节软骨体积的影响：随机安慰剂对照试验的结果, objectType=article, longId=221560, objectId=f24722156043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24722156043, replyNumber=0, likeNumber=66, createdTime=2021-12-06, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24722156043, moduleTitle=A &R: 阿托伐他汀对有症状膝骨关节炎患者膝关节软骨体积的影响：随机安慰剂对照试验的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24722156043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304420, encodeId=90fb130442062, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, objectType=article, longId=221546, objectId=86b522154637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b522154637, replyNumber=0, likeNumber=141, createdTime=2021-12-06, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b522154637, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b522154637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304419, encodeId=ae9b130441972, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, objectType=article, longId=220818, objectId=b1cd22081859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1cd22081859, replyNumber=0, likeNumber=97, createdTime=2021-11-24, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1cd22081859, moduleTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1cd22081859)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304418, encodeId=36401304418ea, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验, objectType=article, longId=220568, objectId=d05e220568ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d05e220568ed, replyNumber=0, likeNumber=110, createdTime=2021-11-20, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d05e220568ed, moduleTitle=Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d05e220568ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304417, encodeId=6fed130441e34, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Clin Pharmacol Ther：有针对性地利用安慰剂效应可有效减少特应性皮炎患者的瘙痒 , objectType=article, longId=219699, objectId=f15921969996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15921969996, replyNumber=0, likeNumber=97, createdTime=2021-11-04, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15921969996, moduleTitle=Clin Pharmacol Ther：有针对性地利用安慰剂效应可有效减少特应性皮炎患者的瘙痒 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15921969996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304416, encodeId=a967130441604, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验, objectType=article, longId=219517, objectId=705a21951e3f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=705a21951e3f, replyNumber=0, likeNumber=118, createdTime=2021-10-31, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=705a21951e3f, moduleTitle=AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=705a21951e3f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304415, encodeId=68b5130441509, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, objectType=article, longId=219450, objectId=ebb921945031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebb921945031, replyNumber=0, likeNumber=86, createdTime=2021-10-30, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebb921945031, moduleTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebb921945031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304414, encodeId=56ef13044147d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果, objectType=article, longId=218828, objectId=bead21882881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bead21882881, replyNumber=0, likeNumber=126, createdTime=2021-10-20, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bead21882881, moduleTitle=Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bead21882881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304413, encodeId=1c151304413a2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Annals of the Rheumatic Diseases: 用奥比妥珠单抗清除B细胞治疗增殖性狼疮性肾炎：一项随机、双盲、安慰剂对照试验, objectType=article, longId=218569, objectId=b5782185696e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5782185696e, replyNumber=0, likeNumber=63, createdTime=2021-10-16, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5782185696e, moduleTitle=Annals of the Rheumatic Diseases: 用奥比妥珠单抗清除B细胞治疗增殖性狼疮性肾炎：一项随机、双盲、安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5782185696e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304412, encodeId=8a3f130441276, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Nat Med：Aramchol在非酒精性脂肪性肝炎患者中的应用：一项随机、双盲、安慰剂对照的2b期试验 , objectType=article, longId=218332, objectId=a64b21833225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a64b21833225, replyNumber=0, likeNumber=129, createdTime=2021-10-11, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a64b21833225, moduleTitle=Nat Med：Aramchol在非酒精性脂肪性肝炎患者中的应用：一项随机、双盲、安慰剂对照的2b期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a64b21833225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304411, encodeId=4001130441170, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Diabetes Obes Metab：利格列酮与安慰剂治疗多囊卵巢综合征女性患者的对比, objectType=article, longId=218159, objectId=3b6e218159b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6e218159b9, replyNumber=0, likeNumber=0, createdTime=2021-10-07, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6e218159b9, moduleTitle=Diabetes Obes Metab：利格列酮与安慰剂治疗多囊卵巢综合征女性患者的对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b6e218159b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304410, encodeId=9edc130441052, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=97, createdTime=2021-10-07, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304409, encodeId=c0d813044096b, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究, objectType=article, longId=217998, objectId=6a9321e99823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9321e99823, replyNumber=0, likeNumber=100, createdTime=2021-10-02, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9321e99823, moduleTitle=Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9321e99823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304408, encodeId=f2a5130440876, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=CDSR：在3-5D期慢性肾病患者中，药物干预与安慰剂、无治疗或常规护理治疗骨质疏松的比较。, objectType=article, longId=217942, objectId=b2fa21e9425c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2fa21e9425c, replyNumber=0, likeNumber=83, createdTime=2021-10-01, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2fa21e9425c, moduleTitle=CDSR：在3-5D期慢性肾病患者中，药物干预与安慰剂、无治疗或常规护理治疗骨质疏松的比较。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2fa21e9425c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304407, encodeId=a3ce130440e71, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=JAMANO：补锌与安慰剂对酗酒的HIV阳性成人死亡风险和HIV疾病进展的影响, objectType=article, longId=217667, objectId=14ef21e667f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14ef21e667f2, replyNumber=0, likeNumber=86, createdTime=2021-09-27, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14ef21e667f2, moduleTitle=JAMANO：补锌与安慰剂对酗酒的HIV阳性成人死亡风险和HIV疾病进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14ef21e667f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304406, encodeId=d93313044063f, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化, objectType=article, longId=217184, objectId=b4eb21e184bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4eb21e184bb, replyNumber=0, likeNumber=77, createdTime=2021-09-17, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4eb21e184bb, moduleTitle=NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4eb21e184bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304405, encodeId=866213044057a, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验 , objectType=article, longId=217120, objectId=9c0421e12073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0421e12073, replyNumber=0, likeNumber=122, createdTime=2021-09-16, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0421e12073, moduleTitle=Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0421e12073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304404, encodeId=05e8130440413, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, objectType=article, longId=217100, objectId=dbfb21e1006b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbfb21e1006b, replyNumber=0, likeNumber=81, createdTime=2021-09-16, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbfb21e1006b, moduleTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbfb21e1006b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

安慰剂

2020-05-29

wleon8895

#安慰剂#

Cancer Med：国内多中心随机双盲II期研究表明安罗替尼（Anlotinib）后线治疗较安慰剂改善晚期或转移性食管鳞癌患者的预后

2021-12-30

wleon8895

#安慰剂#

JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY

2021-12-21

wleon8895

#安慰剂#

A &R: 阿托伐他汀对有症状膝骨关节炎患者膝关节软骨体积的影响：随机安慰剂对照试验的结果

2021-12-06

wleon8895

#安慰剂#

Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL

2021-12-06

wleon8895

#安慰剂#

Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究

2021-11-24

wleon8895

#安慰剂#

Lancet Rheumatology: 利妥昔单抗对风湿性多肌痛患者的疗效：一项双盲、随机、安慰剂对照、概念验证试验

2021-11-20

wleon8895

#安慰剂#

Clin Pharmacol Ther：有针对性地利用安慰剂效应可有效减少特应性皮炎患者的瘙痒

2021-11-04

wleon8895

#安慰剂#

AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验

2021-10-31

wleon8895

#安慰剂#

Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究

2021-10-30

wleon8895

#安慰剂#

Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果

2021-10-20

wleon8895

#安慰剂#

Annals of the Rheumatic Diseases: 用奥比妥珠单抗清除B细胞治疗增殖性狼疮性肾炎：一项随机、双盲、安慰剂对照试验

2021-10-16

wleon8895

#安慰剂#

Nat Med：Aramchol在非酒精性脂肪性肝炎患者中的应用：一项随机、双盲、安慰剂对照的2b期试验

2021-10-11

wleon8895

#安慰剂#

Diabetes Obes Metab：利格列酮与安慰剂治疗多囊卵巢综合征女性患者的对比

2021-10-07

wleon8895

#安慰剂#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2021-10-07

wleon8895

#安慰剂#

Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究

2021-10-02

wleon8895

#安慰剂#

CDSR：在3-5D期慢性肾病患者中，药物干预与安慰剂、无治疗或常规护理治疗骨质疏松的比较。

2021-10-01

wleon8895

#安慰剂#

JAMANO：补锌与安慰剂对酗酒的HIV阳性成人死亡风险和HIV疾病进展的影响

2021-09-27

wleon8895

#安慰剂#

NEPHRUTIX:安慰剂与利妥昔单抗对照评估微小病变型肾病综合征的T细胞亚群变化

2021-09-17

wleon8895

#安慰剂#

Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验

2021-09-16

wleon8895

#安慰剂#

Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！

2021-09-16

科室
- - 订阅+
  - 更多科室
工具
服务